Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorNecmettin Erbakan University
About this trial
Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm.
Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.
Eligibility criteria
Qualifiers
Histological and staging diagnosis of metastatic non-small cell lung cancer
ECOG performance score between 0 and 2
No contraindications for nivolumab
Disqualifiers
Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy
Those with a second primary malignancy undergoing active treatment
Those who have not signed the informed consent form
Those with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov